Lyra Therapeutics, Inc. (NASDAQ:LYRA) Receives $7.13 Consensus Price Target from Analysts

Lyra Therapeutics, Inc. (NASDAQ:LYRA) has received a consensus rating of “Hold” from the six ratings firms that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and one has assigned a buy rating to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $7.13.

Several equities research analysts have issued reports on the stock. BTIG Research reissued a “neutral” rating on shares of Lyra Therapeutics in a report on Monday, May 6th. Bank of America lowered shares of Lyra Therapeutics from a “buy” rating to an “underperform” rating in a report on Tuesday, May 7th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Lyra Therapeutics in a report on Thursday, June 20th. William Blair lowered shares of Lyra Therapeutics from an “outperform” rating to a “market perform” rating in a report on Monday, May 6th. Finally, Jefferies Financial Group lowered shares of Lyra Therapeutics from a “buy” rating to a “hold” rating and lowered their target price for the stock from $10.00 to $0.50 in a report on Tuesday, May 7th.

Institutional Investors Weigh In On Lyra Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its holdings in Lyra Therapeutics by 38.3% during the 1st quarter. Vanguard Group Inc. now owns 1,481,481 shares of the company’s stock worth $9,215,000 after acquiring an additional 410,021 shares during the last quarter. Parkman Healthcare Partners LLC grew its holdings in Lyra Therapeutics by 20.8% during the 4th quarter. Parkman Healthcare Partners LLC now owns 754,885 shares of the company’s stock worth $3,956,000 after acquiring an additional 129,829 shares during the last quarter. Vestal Point Capital LP bought a new stake in Lyra Therapeutics during the 4th quarter worth about $15,720,000. Jump Financial LLC bought a new stake in Lyra Therapeutics during the 4th quarter worth about $88,000. Finally, Heritage Wealth Management Inc. Texas bought a new stake in Lyra Therapeutics during the 4th quarter worth about $52,000. Institutional investors own 95.62% of the company’s stock.

Lyra Therapeutics Price Performance

Shares of Lyra Therapeutics stock opened at $0.31 on Friday. The firm has a market capitalization of $18.75 million, a PE ratio of -0.26 and a beta of -0.01. The company’s fifty day moving average price is $0.30 and its two-hundred day moving average price is $3.21. Lyra Therapeutics has a 52-week low of $0.25 and a 52-week high of $6.79.

Lyra Therapeutics (NASDAQ:LYRA) last announced its quarterly earnings results on Tuesday, April 30th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.09). The business had revenue of $0.53 million during the quarter, compared to the consensus estimate of $0.40 million. Lyra Therapeutics had a negative net margin of 4,099.82% and a negative return on equity of 77.34%. Analysts predict that Lyra Therapeutics will post -1.18 earnings per share for the current fiscal year.

Lyra Therapeutics Company Profile

Lyra Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration.